“AL Amyloidosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.
The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the AL Amyloidosis Pipeline Report:
-
Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years.
-
AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment
-
Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.
-
In May 2024, Immix Biopharma, Inc. (“ImmixBio), a clinical-stage biopharmaceutical company pioneering cell therapies for autoimmune diseases, has announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study. This study investigates the novel, autologous, sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA). The data was presented in a late-breaking oral presentation at the 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Baltimore, MD. All participating patients had relapsed/refractory conditions to the standard-of-care Dara-CyBorD (daratumumab combined with cyclophosphamide, bortezomib, and dexamethasone).
-
In September 2023, The FDA has granted orphan drug designation to the next-generation BCMA-directed CAR T-cell therapy NXC-201 (formerly HBI0101) for treating patients with amyloid light chain (AL) amyloidosis.
AL Amyloidosis Overview
The most prevalent kind of systemic amyloidosis, AL Amyloidosis, is connected to a plasma cell dyscrasia. A condition affecting the bone marrow results in amyloidosis. The bone marrow in the middle of bones creates “plasma cells,” which are blood system cells.
Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight
Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:
-
LambdaMab: HaemaLogiX
-
ZN d5: Zentalis Pharmaceuticals
-
STI-6129: Sorrento Therapeutics
-
Isatuximab: Sanofi
-
Bendamustine: Astellas Pharma GmbH
-
Belantamab mafodotin: GlaxoSmithKline
-
Ixazomib: Takeda Oncology
-
CAEL-101: Caelum Biosciences
AL Amyloidosis Route of Administration
AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
AL Amyloidosis Molecule Type
AL Amyloidosis Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
AL Amyloidosis Pipeline Therapeutics Assessment
-
AL Amyloidosis Assessment by Product Type
-
AL Amyloidosis By Stage and Product Type
-
AL Amyloidosis Assessment by Route of Administration
-
AL Amyloidosis By Stage and Route of Administration
-
AL Amyloidosis Assessment by Molecule Type
-
AL Amyloidosis by Stage and Molecule Type
DelveInsight’s AL Amyloidosis Report covers around 10+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies
Some of the key companies in the AL Amyloidosis Therapeutics Market include:
Key companies developing therapies for AL Amyloidosis are – Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.
AL Amyloidosis Pipeline Analysis:
The AL Amyloidosis pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.
-
AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies
AL Amyloidosis Pipeline Market Drivers
-
Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.
AL Amyloidosis Pipeline Market Barriers
-
However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.
Scope of AL Amyloidosis Pipeline Drug Insight
-
Coverage: Global
-
Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others
-
Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others
-
AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies
-
AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers
Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials
Table of Contents
1. AL Amyloidosis Report Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis Overview
4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment
5. AL Amyloidosis Pipeline Therapeutics
6. AL Amyloidosis Late Stage Products (Phase II/III)
7. AL Amyloidosis Mid Stage Products (Phase II)
8. AL Amyloidosis Early Stage Products (Phase I)
9. AL Amyloidosis Preclinical Stage Products
10. AL Amyloidosis Therapeutics Assessment
11. AL Amyloidosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. AL Amyloidosis Key Companies
14. AL Amyloidosis Key Products
15. AL Amyloidosis Unmet Needs
16 . AL Amyloidosis Market Drivers and Barriers
17. AL Amyloidosis Future Perspectives and Conclusion
18. AL Amyloidosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/